#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Compounders hold on in the GLP-1 market
A June 2026 Gallup survey found nearly 1 in 5 GLP-1 users still take compounded versions, despite FDA crackdowns and pharma lawsuits.
GLP-1 and opioid overdose risk in veterans
A 2026 VHA study linked semaglutide and tirzepatide to lower overdose rates than insulin and SGLT2 inhibitors in veterans with T2D and opioid use disorder.
NVAC charter, GLP-1 telehealth: July 2026
NVAC gets a new charter on 7 July 2026, LifeMD faces GLP-1 telehealth allegations, and Medicare proposes 19% more pay for tobacco counselling.
TTT1: triple therapy for type 1 diabetes
The TTT1 Phase 3 trial tests semaglutide and dapagliflozin added to insulin in overweight adults with type 1 diabetes and poor glycaemic control.
Surgery vs semaglutide: Reddit concerns
NLP of 45,972 Reddit comments: surgery patients cite pain; semaglutide users cite GI and psychological effects. Pre-op anxiety runs 4x higher than post-op.
LifeMD GLP-1 safety claims and Iowa's PBM
Former LifeMD employees allege GLP-1 prescriptions were rushed. An Iowa audit found a PBM may have overcharged Medicaid by over $100 million.
Bariatric surgery volumes fell 39%
Epic Cosmos data show US bariatric surgery peaked in Q4 2022 and fell 39% by Q4 2025. Access to GLP-1 agonists before surgery splits sharply by insurance.
GLP-1 RAs in aging people with HIV
A 2026 review finds semaglutide reduces weight, improves cardiometabolic markers, and may slow epigenetic aging in people with HIV, but key safety gaps remain.
Semaglutide, NAION, and a retracted study
A 2025 paper in Retina on semaglutide and optic nerve risk has been retracted without a stated reason, complicating an already contested safety debate.
T2D and obesity: why treatment falls short
A July 2026 expert review finds clinicians undertreat obesity in type 2 diabetes, leaving a key driver of glycaemic failure and cardiovascular risk unaddressed.
Tirzepatide and kidney function in obesity
A 36-person real-world study found three months of tirzepatide improved eGFR in adults with obesity, with BMI change explaining about 19% of the kidney benefit.
Tirzepatide and platelet volume in obesity
A 60-person retrospective study found tirzepatide reduced mean platelet volume 0.94 fL with a 3.92 BMI-unit drop. What the data shows and where it falls short.